KESHAV
VND 14,200,000
Da ban 1,900+Nhà thuốc Hong Kong có cửa hàng thực tế, đảm bảo hàng chính hãng 100%
In 2022, adagrasib, a prescription medicine targeting KRAS G12C, received accelerated FDA approval in the United States. Use only as directed by a physician.
Còn 10000 trong kho
Indicated for adults with previously treated KRAS G12C-positive advanced non-small cell lung cancer or colorectal cancer.
Adagrasib Cơ chế tác dụng Cơ chế tác dụng ，
2 • (NSCLC) (CRC) Recommended dosage: 600 mg， (2.2) • ， (2.2) 2.1 KRAS G12C ， NSCLC KRAZATI [ (14.1)] ， KRAS G12C ， CRC KRAZATI [ (14.2)] FDA KRAS G12C ， 2.2 KRAZATI 600 mg，
5 Thận trọng • ， ， (2.3, 5.1) • QTc KRAZATI QTc QT ， ， ，
11 Description Adagrasib KRAS G12C ， RAS GTPase C₃₂H₃₅ClFN₇O₂， 604.1 g/mol {(2S)-4-[7-(8- -1- )-2-{[(2S)-1- -2- ]- }-5,6,7,8- [3,4-d] -4- ]-1-(2- -2- ) -2- } Adagrasib Adagrasib pH 1.2 7.4 ，adagrasib > 262 mg/mL < 0.010 mg/mL
Indicated for adults with previously treated KRAS G12C-positive advanced non-small cell lung cancer or colorectal cancer.
2 • (NSCLC) (CRC) Recommended dosage: 600 mg， (2.2) • ， (2.2) 2.1 KRAS G12C ， NSCLC KRAZATI [ (14.1)] ， KRAS G12C ， CRC KRAZATI [ (14.2)] FDA KRAS G12C ， 2.2 KRAZATI 600 mg，
5 Thận trọng • ， ， (2.3, 5.1) • QTc KRAZATI QTc QT ， ， ，
12 12.1 Cơ chế tác dụng Adagrasib KRAS G12C ， KRAS G12C ， KRAS ， ， KRAS Adagrasib KRAS G12C ， KRAS G12C ， Adagrasib ，Adagrasib KRAS G12C CRC 12.2 Adagrasib - Adagrasib QTc
14 14.1 KRYSTAL-1 NCT03785249 adagrasib KRYSTAL-1 KRAS G12C ， ， ECOG 0 1， RECIST v1.1 KRAS G12C adagrasib 600 mg， 6
Chỉ định
Indicated for adults with previously treated KRAS G12C-positive advanced non-small cell lung cancer or colorectal cancer.
Cơ chế tác dụng
Adagrasib Cơ chế tác dụng Cơ chế tác dụng ，
Liều dùng và cách dùng
2 • (NSCLC) (CRC) Recommended dosage: 600 mg， (2.2) • ， (2.2) 2.1 KRAS G12C ， NSCLC KRAZATI [ (14.1)] ， KRAS G12C ， CRC KRAZATI [ (14.2)] FDA KRAS G12C ， 2.2 KRAZATI 600 mg，
Thận trọng
5 Thận trọng • ， ， (2.3, 5.1) • QTc KRAZATI QTc QT ， ， ，
